BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

776 related articles for article (PubMed ID: 22897847)

  • 41. Genetic Alterations and Therapeutic Targeting of Philadelphia-Like Acute Lymphoblastic Leukemia.
    Iacobucci I; Roberts KG
    Genes (Basel); 2021 May; 12(5):. PubMed ID: 34062932
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Genomic profiling of high-risk acute lymphoblastic leukemia.
    Collins-Underwood JR; Mullighan CG
    Leukemia; 2010 Oct; 24(10):1676-85. PubMed ID: 20739952
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.
    Yoda A; Yoda Y; Chiaretti S; Bar-Natan M; Mani K; Rodig SJ; West N; Xiao Y; Brown JR; Mitsiades C; Sattler M; Kutok JL; DeAngelo DJ; Wadleigh M; Piciocchi A; Dal Cin P; Bradner JE; Griffin JD; Anderson KC; Stone RM; Ritz J; Foà R; Aster JC; Frank DA; Weinstock DM
    Proc Natl Acad Sci U S A; 2010 Jan; 107(1):252-7. PubMed ID: 20018760
    [TBL] [Abstract][Full Text] [Related]  

  • 44. ATF7IP as a novel PDGFRB fusion partner in acute lymphoblastic leukaemia in children.
    Kobayashi K; Mitsui K; Ichikawa H; Nakabayashi K; Matsuoka M; Kojima Y; Takahashi H; Iijima K; Ootsubo K; Oboki K; Okita H; Yasuda K; Sakamoto H; Hata K; Yoshida T; Matsumoto K; Kiyokawa N; Ohara A
    Br J Haematol; 2014 Jun; 165(6):836-41. PubMed ID: 24628626
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New strategies in acute lymphoblastic leukemia: translating advances in genomics into clinical practice.
    Mullighan CG
    Clin Cancer Res; 2011 Feb; 17(3):396-400. PubMed ID: 21149616
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hematological characteristics, cytogenetic features, and post-induction measurable residual disease in thymic stromal lymphopoietin receptor (TSLPR) overexpressed B-cell acute lymphoblastic leukemia in an Indian cohort.
    Virk H; Rana S; Sharma P; Bose PL; Yadav DD; Sachdeva MUS; Varma N; Trehan A; Lad D; Khadwal AR; Malhotra P; Sreedharanunni S
    Ann Hematol; 2021 Aug; 100(8):2031-2041. PubMed ID: 34159401
    [TBL] [Abstract][Full Text] [Related]  

  • 47. BCR/ABL1-Like Acute Lymphoblastic Leukemia: From Diagnostic Approaches to Molecularly Targeted Therapy.
    Płotka A; Lewandowski K
    Acta Haematol; 2022; 145(2):122-131. PubMed ID: 34818644
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genomics in acute lymphoblastic leukaemia: insights and treatment implications.
    Roberts KG; Mullighan CG
    Nat Rev Clin Oncol; 2015 Jun; 12(6):344-57. PubMed ID: 25781572
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Characterization of leukemias with ETV6-ABL1 fusion.
    Zaliova M; Moorman AV; Cazzaniga G; Stanulla M; Harvey RC; Roberts KG; Heatley SL; Loh ML; Konopleva M; Chen IM; Zimmermannova O; Schwab C; Smith O; Mozziconacci MJ; Chabannon C; Kim M; Frederik Falkenburg JH; Norton A; Marshall K; Haas OA; Starkova J; Stuchly J; Hunger SP; White D; Mullighan CG; Willman CL; Stary J; Trka J; Zuna J
    Haematologica; 2016 Sep; 101(9):1082-93. PubMed ID: 27229714
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lack of constitutive activation of Janus kinases and signal transduction and activation of transcription factors in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Kanwar VS; Witthuhn B; Campana D; Ihle JN
    Blood; 1996 Jun; 87(11):4911-2. PubMed ID: 8639867
    [No Abstract]   [Full Text] [Related]  

  • 51.
    Jain S; Abraham A
    Arch Pathol Lab Med; 2020 Feb; 144(2):150-155. PubMed ID: 31644323
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Why and how to treat Ph-like ALL?
    Roberts KG
    Best Pract Res Clin Haematol; 2018 Dec; 31(4):351-356. PubMed ID: 30466746
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia.
    Chang Y; Min J; Jarusiewicz JA; Actis M; Yu-Chen Bradford S; Mayasundari A; Yang L; Chepyala D; Alcock LJ; Roberts KG; Nithianantham S; Maxwell D; Rowland L; Larsen R; Seth A; Goto H; Imamura T; Akahane K; Hansen BS; Pruett-Miller SM; Paietta EM; Litzow MR; Qu C; Yang JJ; Fischer M; Rankovic Z; Mullighan CG
    Blood; 2021 Dec; 138(23):2313-2326. PubMed ID: 34110416
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia.
    Opatz S; Polzer H; Herold T; Konstandin NP; Ksienzyk B; Zellmeier E; Vosberg S; Graf A; Krebs S; Blum H; Hopfner KP; Kakadia PM; Schneider S; Dufour A; Braess J; Sauerland MC; Berdel WE; Büchner T; Woermann BJ; Hiddemann W; Spiekermann K; Bohlander SK; Greif PA
    Blood; 2013 Sep; 122(10):1761-9. PubMed ID: 23878140
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tyrosine kinase inhibitor use in pediatric Philadelphia chromosome-positive acute lymphoblastic anemia.
    Hunger SP
    Hematology Am Soc Hematol Educ Program; 2011; 2011():361-5. PubMed ID: 22160058
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Genomic Analyses of Pediatric Acute Lymphoblastic Leukemia Ph+ and Ph-Like-Recent Progress in Treatment.
    Kaczmarska A; Śliwa P; Zawitkowska J; Lejman M
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34203891
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 'Evaluation of adverse prognostic gene alterations & MRD positivity in BCR::ABL1-like B-lineage acute lymphoblastic leukaemia patients, in a resource-constrained setting.
    Gupta DG; Varma N; Sreedharanunni S; Abdulkadir SA; Naseem S; Sachdeva MUS; Binota J; Bose P; Malhotra P; Khadwal A; Varma S
    Br J Cancer; 2023 Jul; 129(1):143-152. PubMed ID: 37156894
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia.
    Weston BW; Hayden MA; Roberts KG; Bowyer S; Hsu J; Fedoriw G; Rao KW; Mullighan CG
    J Clin Oncol; 2013 Sep; 31(25):e413-6. PubMed ID: 23835704
    [No Abstract]   [Full Text] [Related]  

  • 59. Pre-B acute lymphoblastic leukaemia recurrent fusion, EP300-ZNF384, is associated with a distinct gene expression.
    McClure BJ; Heatley SL; Kok CH; Sadras T; An J; Hughes TP; Lock RB; Yeung D; Sutton R; White DL
    Br J Cancer; 2018 Apr; 118(7):1000-1004. PubMed ID: 29531323
    [TBL] [Abstract][Full Text] [Related]  

  • 60. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report.
    Martinelli G; Iacobucci I; Storlazzi CT; Vignetti M; Paoloni F; Cilloni D; Soverini S; Vitale A; Chiaretti S; Cimino G; Papayannidis C; Paolini S; Elia L; Fazi P; Meloni G; Amadori S; Saglio G; Pane F; Baccarani M; Foà R
    J Clin Oncol; 2009 Nov; 27(31):5202-7. PubMed ID: 19770381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.